Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Bernard Moss

Showing results (281-290 of 308) with videos related to

Pageof 31
Sort By:
Plos One|October 11, 2012
Heterologous prime-boost regimens using rAd35 and rMVA vectors elicit stronger cellular immune responses to HIV proteins than homologous regimensSilvia Ratto-Kim, Jeffrey R Currier, Josephine H Cox, et al.
AIDS Research and Human Retroviruses|January 15, 2005
DNA/MVA vaccine for HIV type 1: effects of codon-optimization and the expression of aggregates or virus-like particles on the immunogenicity of the DNA primeJames M Smith, Rama Rao Amara, David Campbell, et al.
AIDS Research and Human Retroviruses|October 31, 2003
Gp120-alum boosting of a Gag-Pol-Env DNA/MVA AIDS vaccine: poorer control of a pathogenic viral challengeSuzan L Buge, Hak-Ling Ma, Rama R Amara, et al.
Vaccine|December 20, 2011
SIVmac239 MVA vaccine with and without a DNA prime, similar prevention of infection by a repeated dose SIVsmE660 challenge despite different immune responsesLilin Lai, Sue-Fen Kwa, Pamela A Kozlowski, et al.
Immunology and Cell Biology|January 6, 2026
Humoral epitope dominance and immune imprinting by SARS-CoV-1 and SARS-CoV-2 vaccinesDeborah L Burnett, Ania Moxon, Anupriya Aggarwal, et al.
The Journal of Infectious Diseases|September 24, 2008
Broad immunogenicity of a multigene, multiclade HIV-1 DNA vaccine boosted with heterologous HIV-1 recombinant modified vaccinia virus AnkaraEric Sandström, Charlotta Nilsson, Bo Hejdeman, et al.
Journal of Immunology (Baltimore, Md. : 1950)|September 30, 2016
High Doses of GM-CSF Inhibit Antibody Responses in Rectal Secretions and Diminish Modified Vaccinia Ankara/Simian Immunodeficiency Virus Vaccine Protection in TRIM5α-Restrictive MacaquesSunil Kannanganat, Linda S Wyatt, Sailaja Gangadhara, et al.
Journal of Virology|May 22, 2002
Critical role for Env as well as Gag-Pol in control of a simian-human immunodeficiency virus 89.6P challenge by a DNA prime/recombinant modified vaccinia virus Ankara vaccineRama Rao Amara, James M Smith, Silvija I Staprans, et al.
Plos One|November 19, 2010
Phase I safety and immunogenicity evaluation of MVA-CMDR, a multigenic, recombinant modified vaccinia Ankara-HIV-1 vaccine candidateJeffrey R Currier, Viseth Ngauy, Mark S de Souza, et al.
Journal of Virology|July 29, 2016
Virus-Like Particles Displaying Trimeric Simian Immunodeficiency Virus (SIV) Envelope gp160 Enhance the Breadth of DNA/Modified Vaccinia Virus Ankara SIV Vaccine-Induced Antibody Responses in Rhesus MacaquesSmita S Iyer, Sailaja Gangadhara, Blandine Victor, et al.
Pageof 31

Showing results (281-290 of 308) with videos related to

Sort By:
Pageof 31
Plos One|October 11, 2012
Heterologous prime-boost regimens using rAd35 and rMVA vectors elicit stronger cellular immune responses to HIV proteins than homologous regimensSilvia Ratto-Kim, Jeffrey R Currier, Josephine H Cox, et al.
AIDS Research and Human Retroviruses|January 15, 2005
DNA/MVA vaccine for HIV type 1: effects of codon-optimization and the expression of aggregates or virus-like particles on the immunogenicity of the DNA primeJames M Smith, Rama Rao Amara, David Campbell, et al.
AIDS Research and Human Retroviruses|October 31, 2003
Gp120-alum boosting of a Gag-Pol-Env DNA/MVA AIDS vaccine: poorer control of a pathogenic viral challengeSuzan L Buge, Hak-Ling Ma, Rama R Amara, et al.
Vaccine|December 20, 2011
SIVmac239 MVA vaccine with and without a DNA prime, similar prevention of infection by a repeated dose SIVsmE660 challenge despite different immune responsesLilin Lai, Sue-Fen Kwa, Pamela A Kozlowski, et al.
Immunology and Cell Biology|January 6, 2026
Humoral epitope dominance and immune imprinting by SARS-CoV-1 and SARS-CoV-2 vaccinesDeborah L Burnett, Ania Moxon, Anupriya Aggarwal, et al.
The Journal of Infectious Diseases|September 24, 2008
Broad immunogenicity of a multigene, multiclade HIV-1 DNA vaccine boosted with heterologous HIV-1 recombinant modified vaccinia virus AnkaraEric Sandström, Charlotta Nilsson, Bo Hejdeman, et al.
Journal of Immunology (Baltimore, Md. : 1950)|September 30, 2016
High Doses of GM-CSF Inhibit Antibody Responses in Rectal Secretions and Diminish Modified Vaccinia Ankara/Simian Immunodeficiency Virus Vaccine Protection in TRIM5α-Restrictive MacaquesSunil Kannanganat, Linda S Wyatt, Sailaja Gangadhara, et al.
Journal of Virology|May 22, 2002
Critical role for Env as well as Gag-Pol in control of a simian-human immunodeficiency virus 89.6P challenge by a DNA prime/recombinant modified vaccinia virus Ankara vaccineRama Rao Amara, James M Smith, Silvija I Staprans, et al.
Plos One|November 19, 2010
Phase I safety and immunogenicity evaluation of MVA-CMDR, a multigenic, recombinant modified vaccinia Ankara-HIV-1 vaccine candidateJeffrey R Currier, Viseth Ngauy, Mark S de Souza, et al.
Journal of Virology|July 29, 2016
Virus-Like Particles Displaying Trimeric Simian Immunodeficiency Virus (SIV) Envelope gp160 Enhance the Breadth of DNA/Modified Vaccinia Virus Ankara SIV Vaccine-Induced Antibody Responses in Rhesus MacaquesSmita S Iyer, Sailaja Gangadhara, Blandine Victor, et al.
Pageof 31